Abstract
Naturally pyrazinamide (PZA)–resistant Mycobacterium bovis and acquired PZA–resistant M. tuberculosis strains lose pyrazinamidase (PZase). To investigate the molecular mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase. Mutations in pncA were identified in both types of PZA–resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility. These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA–resistant clinical isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons — Florida and New York, 1988–1991. Mortal. Morbid. Weekly Rep. 40, 585–591 (1991).
Block, A.B. et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271, 665–671 (1994).
Bloom, B.R. & Murray, C.J.L. Tuberculosis: Commentary on a reemergent killer. Science 257, 1055–1064 (1992).
Zhang, Y., Heym, B., Alien, B., Young, D. & Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591–593 (1992).
Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227–230 (1994).
Telenti, A. et al. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341, 647–650 (1993).
Finken, M., Kirschner, P., Meier, A., Wrede, A. & Bottger, E.C. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol. Microbiol. 9, 1239–1246 (1993).
Mitchison, D.A. The action of antituberculosis drugs in short course chemotherapy. Tubercle 66, 219–225 (1985).
McCune, R.M., Tompsett, R. & McDermott, W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. J. Exp. Med. 104, 763–802 (1956).
Heifets, L. & Lindholm-Levy, P. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145, 1223–1225 (1992).
Yeager, R.L., Munroe, W.G. & Dessau, F.I. Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65, 523–534 (1952).
Konno, K., Feldman, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461–469 (1967).
McClatchy, J.K., Tsang, A.Y. & Cernich, M.S. Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agent. Chemother. 20, 556–557 (1981).
Trivedi, S.S. & Desai, S.G. Pyrazinamidase activity of Mycobacterium tuberculosis — a test of sensitivity to pyrazinamide. Tubercle 68, 221–224 (1987).
Konno, K., Nagayama, H. & Oka, S. Nicotinamidase in mycobacteria: A method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 184, 1743–1744 (1959).
Collins, C.H., Grange, J.M. & Yates, M.D. Tuberculosis Bacteriology. 59–66 (Butterworths, London, 1985).
Foster, J.W. & Moat, A.G. Nicotinamide adenine dinucleotide biosynthesis and pyridine nucleotide cycle metabolism in microbial systems. Microbiol. Rev. 44, 83–105 (1980).
Bonicke, R. & Lisboa, B.P. Typendifferenzierung der Tuberkulosebakterien mit Hilfe des Nikotinamidasetests. Tuberkuloseartzt 13, 377 (1959).
Jerlstrom, P.G., Bezjak, D.A., Jennings, M.P. & Beacham, I.R. Structure and expression in Escherichia coli K-12 of the L-asparaginase I-encoding ansA gene and its flanking regions. Gene 78, 37–46 (1989).
Mackaness, G.B. The intracellular activation pyrazinamide and nicotinamide. Am. Rev. Tuberc. 74, 718–728 (1956).
Tarshis, M.S. & Weed, W.A. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am. Rev. Tuberc. 67, 391–395 (1953).
McDermott, W. & Tomsett, R. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am. Rev. Tuberc. 70, 748–754 (1954).
Crowle, A.J., Dahl, R., Ross, E. & May, M.H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or M. avium in cultured human macrophages are not acidic. Infect. Immun. 59, 1823–1831 (1991).
World Health Organization. Zoonotic tuberculosis (Mycobacterium bovis): Memorandum from a WHO meeting. Bull. World Health Organ. 72, 851–857 (1994).
Rodriguez, J.G., Mejia, G.A., Del Portillo, P., Patarroyo, M.E. & Murillo, L.A. Species-specific identification of Mycobacterium bovis by PCR. Microbiology. 141, 2131–2138 (1995).
Orita, M., Suzuki, Y., Sekiya, T. & Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5, 874–879 (1989).
Dickinson, J.M. & Mitchison, D.A. Observation in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 51, 389–396 (1970).
Klemens, S.P., Sharpe, C.A. & Cynamon, M.H. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob. Agent. Chemother. 40, 14–16 (1996).
Zhang, Y. et al. Alterations in the superoxide dismutase gene of an isoniazid-resistant strain of Mycobacterium tuberculosis. Infect. Immun. 60, 2160–2165 (1992).
Foster, J.W., Kinney, D.M. & Moat, A.G. Pyridine nucleotide cycle of Salmonella typhimurium: Isolation and characterization of pncA, pncB, and pncC mutants and utilization of exogenous nicotinamide adenine dinucleotide. J. Bacterial. 137, 1165–1175 (1979).
Saiki, R.K. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487–491 (1988).
Sambrook, J., Fritsch, E.F. & Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd edn. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989).
Garbe, T. et al. Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology 140, 133–138 (1994).
Zhang, Y., Garbe, T. & Young, D. Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol. 8, 521–524 (1993).
Wayne, L.G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109, 147–151 (1974).
Skinner, P. et al. A bone marrow-derived macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob. Agent. Chemother. 38, 2557–2563 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scorpio, A., Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2, 662–667 (1996). https://doi.org/10.1038/nm0696-662
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0696-662
This article is cited by
-
Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model
Scientific Reports (2023)
-
Near-field sensor array with 65-GHz CMOS oscillators can rapidly and comprehensively evaluate drug susceptibility of Mycobacterium
Scientific Reports (2023)
-
Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update
Current Microbiology (2022)
-
Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide
Nature Communications (2021)
-
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
Clinical Pharmacokinetics (2021)